Last $1.70 USD
Change Today -0.03 / -1.73%
Volume 18.9K
SNTI On Other Exchanges
Symbol
Exchange
OTC BB
OTC US
As of 5:20 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

senesco technologies inc (SNTI) Snapshot

Open
$1.73
Previous Close
$1.73
Day High
$1.73
Day Low
$1.58
52 Week High
12/30/13 - $6.35
52 Week Low
08/20/14 - $1.58
Market Cap
11.7M
Average Volume 10 Days
27.3K
EPS TTM
$-2.13
Shares Outstanding
6.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SENESCO TECHNOLOGIES INC (SNTI)

Related News

No related news articles were found.

senesco technologies inc (SNTI) Related Businessweek News

No Related Businessweek News Found

senesco technologies inc (SNTI) Details

Senesco Technologies, Inc., a development stage biotechnology company, engages in the development of products and technologies for human therapeutic applications to treat cancer and inflammatory diseases. The company’s therapeutic candidate includes SNS01-T, which is in Phase Ib/IIa clinical study for the potential treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkin B-cell lymphomas. It also develops and licenses gene technologies to enhance the quality and productivity of fruits, flowers, vegetables, forestry species, agronomic crops, and biofuel feedstock crops through the control of cell death and growth in plants. The company was founded in 1964 and is based in Bridgewater, New Jersey.

11 Employees
Last Reported Date: 12/12/13
Founded in 1964

senesco technologies inc (SNTI) Top Compensated Officers

President
Total Annual Compensation: $273.9K
Scientific Founder
Total Annual Compensation: $67.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $178.0K
Vice President of Preclinical Development
Total Annual Compensation: $161.0K
Compensation as of Fiscal Year 2013.

senesco technologies inc (SNTI) Key Developments

Senesco Technologies, Inc. Announces Management Changes

Senesco Technologies Inc. announced the appointment of Ronald A. Martell as chief executive officer at the 2014 BIO International Convention in San Diego. Martell will be replacing acting CEO, Vaughn V. Smider, M.D., Ph.D. Smider will remain chief scientific officer and a member of the board of directors. For more than 25 years, Martell has led successful companies in the biotech industry. Most recently he was president and CEO of NeurogesX.

Senesco Seeks Acquisitions

Senesco Technologies Inc. (OTCBB:SNTI) is looking for acquisition opportunities. Ronald A. Martell Chief Executive Officer of Senesco Technologies said, "We will look to be opportunistic to acquire clinical stage assets to continue to build our portfolio and enable our strategy."

Senesco Technologies Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM

Senesco Technologies Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTI:US $1.70 USD -0.03

SNTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTI.
View Industry Companies
 

Industry Analysis

SNTI

Industry Average

Valuation SNTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 100.4x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 57.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SENESCO TECHNOLOGIES INC, please visit www.senesco.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.